Coherus Oncology (NASDAQ:CHRS) Chief Executive Denny Lanfear outlined the company’s immuno-oncology strategy at the Jefferies Global Healthcare Conference, emphasizing commercial growth for LOQTORZI and clinical development plans for tagmokitug and casdozokitug. Lanfear said Coherus has been a “full-on immuno-oncology company” for about a year after divesting its biosimilar business roughly two years ago. He described […]